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18Quantitative Analysis of Retinal Structure Using
Spectral-Domain Optical Coherence
Tomography in RPGR-Associated RetinopathyJAMES J.L. TEE, JOSEPH CARROLL, ANDREW R. WEBSTER, AND MICHEL MICHAELIDES PURPOSE: To quantify retinal structure and progres-
sion using spectral-domain optical coherence tomography
(SDOCT) in patients with retinitis pigmentosa (RP)
associated with retinitis pigmentosa GTPase regulator
gene (RPGR) mutations.
 DESIGN: Retrospective observational case series.
 METHODS: SETTING: Moorfields Eye Hospital, London,
United Kingdom. SUBJECTS: Both eyes of 32 patients.
SDOCT follow-up period of>1 year (3.1 ± 1.4 years).
MAIN OUTCOME MEASURES: Ellipsoid zone (EZ) width
(EZW) and outer nuclear layer (ONL) and inner retinal
layer (IRL) thickness measurements. Progression rates,
interocular symmetry, and association with age and
genotype were investigated.
 RESULTS: Significant differences were observed be-
tween baseline and final measurements of EZW and
ONL thickness, but not for IRL thickness. Baseline and
final EZWs were 2438 ± 1646 mm and 1901 ±
1423 mm for right eyes (P< .0001); 2420 ± 1758 mm
and 1922 ± 1482 mm for left eyes (P< .0001). EZW
constriction rates were 176.6 ± 130.1 mm/year and
173.1 ± 146.8mm/year for right and left eyes. ONL thin-
ning rates were 2.58 ± 2.85mm/year and 2.52 ± 3.54mm/
year for right and left eyes. Interocular differences in EZW
andONLprogressionwere not significant (P[ .8609 and
P[ .6735, respectively). Strong correlations were found
between EZW constriction rates of right and left eyes
(rs[ 0.627, P[ .0002) and between EZW constriction
and baseline EZW (rs[ 0.714, P< .0001). There was
moderate negative correlation between EZW constriction
and age (rs[L0.532,P< .0001). Correlation between
ONL thinning and age was not significant, as were differ-
ences between EZW and ONL progression rates with
respect to genotype.
 CONCLUSIONS: This study provides SDOCT progres-
sion rates for RPGR-associated RP. There is overallupplemental Material available at AJO.com.
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R
ETINITIS PIGMENTOSA (RP) IS A GROUP OF GENETI-
cally diverse disorders characterized initially by
nyctalopia, progressive visual field constriction,
and finally decreased central vision in the advanced stage.
The prevalence of RP is estimated to be 1:3000, with
30%–40% of cases inherited via an autosomal dominant
retinitis pigmentosa, 45%–60% via an autosomal recessive
route (ADRP), and 5%–15% as an X-linked (XL) trait.1–5
RPGR mutations account for 70%–80% of XLRP6–8 with
RP2 variants accounting for a further 6%–20%.7–11
RPGR-associated RP is particularly severe, with an early
onset of disease in childhood. There is marked phenotypic
heterogeneity in the condition, and rate of disease
progression varies between affected individuals.12 RPGR
mutations have also been associated with other clinical
phenotypes, including cone-rod dystrophy, macular atro-
phy, and, rarely, syndromic XLRP (OMIM*312610).12,13
Less phenotypic variation is seen with RP2, with XLRP
being the only associated clinical phenotype
(OMIM*300757).14 Unlike RPGR-associated RP, early
macular involvement with reduced visual acuities has
been described as a distinguishing feature in RP2-associated
RP.8,15 An earlier study, however, did not find differences
betweenRP2 andRPGR phenotypes.16 Despite overlapping
symptoms of RPGR- and RP2-associated RP, the renewed
effort in recent years to distinguish between genetic muta-
tions that give rise to disease phenotypes is crucial with
the advent of gene-directed therapy and other novel inter-
ventions.17
Spectral-domain optical coherence tomography
(SDOCT) is an established modality for studying retinal
structure in vivo. In subjects with RP, there exists a contin-
uum from apparently healthy central retinal tissue to
diseased peripheral retina (termed the ‘‘transition zone’’),
which can be categorized into distinct regions based on
retinal morphology. Jacobson and associates described 4
subzones, with emphasis on the appearance of the photore-
ceptor outer nuclear layer (ONL) and inner retinal layers,0002-9394
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from (1) normal retina centrally to (2) regions of ONL
thinning, (3) ONL loss accompanied by inner nuclear layer
thickening, and finally (4) retinal atrophy at the periph-
ery.18 Hood and associates included an assessment of the
photoreceptor outer segment (OS) in addition to ONL
thickness in their definition of the transition zone.19 The
structurally intact foveal center extends centrifugally into
a region characterized by OS thinning, then into a region
where there is both OS and ONL layer thinning, followed
by total loss of OS and ellipsoid zone (EZ) band, and finally
into a region where the ONL layer has completely thinned
down to lie at an asymptote to the retinal pigment
epithelium (RPE).19
Assessment of the rate of progression in XLRP has been
undertaken by measurement of EZ constriction over time
on line scans,20–22 and to a lesser extent by calculating
global average retinal thickness derived from volume scan
segmentation of photoreceptor and ONL layers.21 The reli-
ability of these metrics to quantify disease progression has
also been explored.21 However, these studies do not distin-
guish between RPGR and other genetic causes of XLRP,
and are potentially limited by eye selection bias.20–22
The use of EZ width metrics as a marker for disease
severity and progression in XLRP correlates well with
retinal function, with intact foveal EZ associated with
good visual acuity23 and the length of intact EZ closely
correlated to the extent of the preserved visual field.24 A
drop of 8 dB in retinal sensitivity between regions where
EZ is present compared with adjacent regions of EZ loss
has been described25 and substantiated by the discovery
that the greatest rate of retinal sensitivity decline occurred
in regions on either side of EZ band disappearance, as
opposed to the central 10 degrees, where the photoreceptors
are still relatively healthy.26 ONL thinning is also noted to
occur in areas of declining sensitivity.18,26,27 Regions of
ONL loss are often accompanied by inner retinal
thickening, as reported in ADRP associated with RHO, in
Usher syndrome type 1 associated with MYO7A, and in
XLRP associated with RPGR.18,27,28 However, others
have observed that any increase in inner retinal thickness
is owing to thickening of the nerve fiber layer (NFL).19,29
There have also been observations that NFL thinning or a
combination of thickening and thinning can occur.30,31
RPGR is an important focus for gene therapy research,
with recent successes demonstrated in animal models32,33
and human clinical trials in preparation.33 It is anticipated
that SDOCT imaging will be a crucial modality in the
assessment of retinal structure pre- and post intervention.
The current lack of natural history data in individuals
harboring pathogenic mutations in RPGR, however, poses
a limiting factor. As such, the aims of this study were to
investigate and quantify the following in patients with
molecularly confirmed RPGR RP: (1) EZ width (EZW)
and ONL and inner retinal layer (IRL) thickness on
SDOCT; (2) progression rates of the aforementioned met-
rics; (3) interocular symmetry of baseline measurementsVOL. 178 SPECTRAL-DOMAIN OCT INand progression rates; (4) association between baseline
measurements and age; (5) association between progression
rates and age; and (6) association between progression rates
and baseline EZW. This study specifically describes findings
in patients with RPGR-associated RP.METHODS
THIS RETROSPECTIVE OBSERVATIONAL SDOCT STUDY WAS
registered and approved by the R&D Department of Moor-
fields Eye Hospital, London, United Kingdom, with adher-
ence to the Declaration of Helsinki kept throughout the
study. A search of the Moorfields Inherited Eye Disease
Database was last performed on April 7, 2016, to identify
male subjects with likely disease-causing sequence variants
in RPGR resulting in an RP phenotype, who have previ-
ously attended the Medical Retina Genetics clinics at
Moorfields Eye Hospital, London, United Kingdom. Pa-
tients with SDOCT follow-up of more than 1 year and in
whom the EZ was located within the imaging borders
were selected for inclusion.
Bidirectional sequencing to test for mutations in RPGR
exons 1–14 and Open Reading Frame 15 (ORF15) were
performed for all patients at the Central Manchester Uni-
versity Hospitals Genomic Diagnostics Laboratory, UK.
Mutations that were confirmed likely to be pathogenic
either have been reported in the literature or, in the case
of novel mutations, were predicted to result in the disrup-
tion of normal protein translation. We additionally cross-
referenced the mutations with the RPGR variant database
that is maintained by the Medical Research Council Hu-
man Genetics Unit, Edinburgh, UK,34,35 to corroborate
novel mutations. Mutations were also entered into
Mutalyzer 2.0.23 (https://mutalyzer.nl/) to confirm
disruption of protein translation.36
Ophthalmic photographers acquired images on the Spec-
tralis OCT device (Heidelberg Engineering, Heidelberg,
Germany). Where available, horizontal high-resolution
line scans with automatic real-time tracking were selected
for analysis and supplemented with transfoveal line scans
obtained from horizontal volume scans. Images were
analyzed with vendor software (Heidelberg Eye Explorer
Region Finder Version 2.4.3.0) in a 1:1 micron setting
with the following method: The foveal center is marked
on the baseline transfoveal OCT image (Figure 1, annota-
tion ‘a’) and the corresponding point marked on the accom-
panying baseline HRA fundus image (Figure 1, annotation
‘b’). The baseline HRA overlay is copied and pasted on the
final HRA fundus image as per vendor software (Figure 1,
annotation ‘c’). The vertical OCT marker position on the
final image is then adjusted to correspond to that shown
on the final HRA image (Figure 1, annotation ‘d’). This en-
sures the same location is selected as the foveal center on
both baseline and final OCT images, and is particularly19RPGR RETINOPATHY
FIGURE 1. Baseline (Top) and final (Bottom) optical coherence tomography (OCT) images of a patient with RPGR-associated
retinopathy, taken with a 1.5-year interval. Ellipsoid zone width was 1615 mm at baseline and 1359 mm on final OCT. Nasal outer
nuclear layer (ONL) thickness was 84mmat baseline and 63mmon final OCT.Nasal inner retinal layer (IRL) thickness was 105mm
at baseline and 119 mm on final OCT. Temporal ONL thickness was 74 mm at baseline and 51 mm on final OCT. Temporal IRL
thickness was 131 mm at baseline and 143 mm on final OCT.important when locating corresponding positions for follow-
up measurements of retinal thickness. Next, nasal and tem-
poral EZ edges on baseline and final OCTs are marked with
the arrow tool (Figure 1, annotations ‘e’ and ‘f’). This is taken
at the point of EZ disappearance into the proximal RPE
border. EZWismeasuredbydrawing a straight line tangential
to the distal RPE border with the caliper tool for both images
(Figure 1, annotation ‘g’). Horizontal distances between
foveal center and both nasal and temporal EZ edges are
measured on the final OCT (Figure 1, annotations ‘h’ and
‘i’) and the same distances are subsequently marked out on
the baseline OCT (Figure 1, annotation ‘h’ and ‘i’). This
step enables retinal thickness measurements to be taken at
corresponding retinal locations on both baseline and final
OCT images (ie, at the ‘‘transition points’’). Vertical thick-
nessmeasures of both theONLand IRL are taken orthogonal
to the retina at the nasal and temporal transition points of
both baseline and final OCT images.
ONL thickness was measured from the border along the
outer plexiform layer/inner nuclear layer (OPL/INL) to the
external limiting membrane (ELM). The OPL/INL border
was used for ONL thickness measure instead of the outer
nuclear layer/outer plexiform layer (ONL/OPL) border, as
the OPL/INL border is more clearly demarcated than the
ONL/OPL border, which also contains Henle fibers. IRL
thickness was measured from the ganglion cell layer/nerve
fiber layer (GCL/NFL) border to the OPL/INL border. As
such, the IRL thickness measure contains the GCL, IPL,
and INL but not the NFL. Image magnification is optimally
adjusted throughout to facilitate the identification of
retinal borders and layers.20 AMERICAN JOURNAL OFStatistical analysis was performed with XLSTAT
version 2014.6.02 (Addinsoft, New York, New York,
USA) software. Data are expressed as mean values, with
standard deviation and 95% confidence intervals provided
where stated. Differences in baseline and final EZW,
ONL, and IRL measurements were assessed for signifi-
cance with the Wilcoxon signed rank test. Intraocular
and interocular differences in EZW and ONL progression
rates were also investigated with the aforementioned test.
Spearman correlation coefficient was calculated to inves-
tigate interocular associations of symmetry for baseline
EZW and ONL thickness; interocular symmetry of EZW
and ONL progression rates; association between age and
baseline EZW and ONL thickness; association between
baseline EZW and progression rate; and association be-
tween age and EZW progression rate. Study eyes were
categorized into 2 groups, those with mutations in exons
1–14 or ORF15, prior to conducting a Mann-Whitney
test for the purpose of investigating potential differences
in progression rates with respect to genotype. Study eyes
were further recategorized into 2 groups based on
predicted effects of their mutations: those with null allele
mutations (premature stop codons or frameshifts leading
to premature stop codons in exons 1–14) or those with
mutations likely to result in translation of a variant pro-
tein product (missense mutations and mutations in
ORF15).37 Eyes of 2 patients with splice site mutations
were excluded from this analysis owing to the greater
challenge in predicting their effects.37 Significance level
alpha was set at 0.05 and 2-tailed P values were calculated
for all statistical testing.JUNE 2017OPHTHALMOLOGY
FIGURE2. Flowchart documenting the recruitment of subjects withRPGR-associated retinopathy as per the inclusion and exclusion
criteria.RESULTS
THIRTY-TWO PATIENTS HAD BOTH EYES THAT MET THE
inclusion criteria, as shown on the flowchart in Figure 2.
Age at presentation, as calculated from time of birth to
time of baseline image acquisition, was 19.1 6 7.9 years.VOL. 178 SPECTRAL-DOMAIN OCT INOut of the 32 patients, 22 were white, 2 South Asian, 1
black, and 1 Middle-Eastern, and 6 others had unspecified
ethnic backgrounds. Fourteen patients had pathogenic mu-
tations in RPGR exons 1–14, and 18 patients had muta-
tions within RPGR ORF15. As shown in Table 1, 7 out
of 10 novel mutations lay within RPGR exons 1–14. All21RPGR RETINOPATHY
TABLE 1. RPGR Mutations of All Study Patients and Their
Predicted Effects on Protein Translation
Exon
Genetic Mutation (Based
on Accession Number
NM_001034853.1) Effect
Exons 1–14 Exon 6–11 deletion* Premature termination
Exon 7 deletion* Premature termination
c.799G>A Missense mutation
c.836_934þ1276del Exon/intron 8 splice site
c.880delG* Premature termination
c.891_892delAA Premature termination
c.914dupA* Premature termination
c.1234C>T Premature termination
c.1243_1244delAG* Premature termination
c.1387C>T* Premature termination
c.1429G>T* Premature termination
c.1572þ1G>A Exon/intron 13 splice site
ORF 15 c.2045_2046dupGT* Premature termination
c.2238delA* Premature termination
c.2245G>T Premature termination
c.2384delA Premature termination
c.2405_2406delAG Premature termination
c.2476_2477delAG Premature termination
c.2586_2587delGG Premature termination
c.2601_2602delGG Premature termination
c.2625dupA Premature termination
c.2907_2910delAGGA Premature termination
c.2993_2997delAAGGG Premature termination
ORF ¼ open reading frame.
Novel mutations are indicated by an asterisk.novel mutations were predicted to result in premature
termination. The interval between baseline and final
OCT scans was 3.1 6 1.4 years. Baseline and final EZW,
ONL, and IRL thickness values with corresponding
P values calculated from intraocular comparisons are
provided in Table 2.
As shown in Figure 3, a very strong and significant
correlation is present between baseline EZW of right and
left eyes (Spearman correlation coefficient, rs ¼ 0.931,
P< .0001). Baseline ONL thickness correlated moderately
between right and left eyes (rs ¼ 0.509, P ¼ .0033).
A significant negative correlation was found between
baseline EZW and age, indicating a smaller baseline EZW
in older eyes (rs ¼ 0.594, P < .0001). Correlation
between baseline ONL thickness and age was weak
(rs ¼ 0.250, P ¼ .0467).
As shown in Table 2, the differences between baseline
and final values of EZW and ONL thickness measurements
were significant, in contrast to the baseline and final IRL
values. EZW and ONL progression rates together with
corresponding P values obtained from intraocular and
interocular comparisons are provided in Table 3. Progres-
sion rates for IRL were not calculated, as baseline and final
values for this metric did not differ significantly. EZW22 AMERICAN JOURNAL OFconstriction occurred at a rate of 176.6 6 130.1 mm/year
for right eyes and 173.1 6 146.8 mm/year for left eyes.
Average rate of ONL thinning was 2.58 6 2.85 mm/year
and 2.52 6 3.54 mm/year for right and left eyes, respec-
tively. Intraocular and interocular differences in EZW
andONL progression rates were not statistically significant.
A scatterplot of interocular EZW progression rates is
shown in Figure 4. A significant and strong correlation is
found in the EZW progression rates between right and
left eyes (rs¼ 0.627, P¼ .0002), but not for ONL thinning
rates between right and left eyes (rs ¼ 0.172, P ¼ .3432).
The association between rates of disease progression
with respect to baseline EZW and age were investigated.
Figure 5 shows a scatterplot of EZW constriction rates vs.
their baseline EZW. There is a strong and significant corre-
lation, indicating that progression as measured by rate of
EZW constriction is greater in eyes with larger baseline
EZW (rs ¼ 0.714, P < .0001). There was a moderate and
negative correlation between EZW constriction rates
with age (rs ¼ 0.532, P < .0001). Correlation between
ONL thinning rates with age were, however, weak and
not statistically significant (rs ¼ 0.172, P ¼ .1748).
To investigate potential differences in EZW and ONL
progression rates as conferred by genotype, eyes were cate-
gorized into 2 groups: those with either exon 1–14 muta-
tions or mutations in ORF15. Statistical testing with the
Mann-Whitney test indicated that differences were not sig-
nificant (EZW constriction rate for the exon 1–14 group
was 172.47 6 149.38 mm/year compared to 176.63 6
129.87 mm/year for the ORF15 group, P ¼ .7117. ONL
thinning rate for the exon 1–14 group was 1.73 6
2.45 mm/year compared to 3.19 6 3.56 mm/year for the
ORF15 group, P ¼ .0667).
Eyes were recategorized into 2 groups to aid investigation
of potential differences in EZW and ONL progression rates
as conferred by mutation type: those with null alleles or
those with mutations that give rise to variant protein prod-
ucts. Statistical testing with the Mann-Whitney test indi-
cated that differences for EZW constriction rate were
insignificant between the groups (EZW constriction rate
for the null allele group was 199.00 6 158.12 mm/year
compared to 171.356 128.43 mm/year for the variant pro-
tein product group, P ¼ .5861). Differences in ONL thin-
ning rate were borderline significant, with a lower ONL
thinning rate for the null allele group of 1.69 6 2.44 mm/
year compared to 3.206 3.47 mm/year for the variant pro-
tein product group, P ¼ .0437.DISCUSSION
WE PRESENT THE FIRST COMPREHENSIVE SERIES DESCRIBING
progression rates in both eyes of molecularly proven RPGR-
associated RP patients using metrics derived from the tran-
sition zone as characterized by Hood and associates.19 EZWJUNE 2017OPHTHALMOLOGY
TABLE 2. Values for Baseline and Final Optical Coherence Tomography–Derived Metrics for Study Subjects With RPGR-Associated
Retinopathy
Right Eyes (N ¼ 32) Left Eyes (N ¼ 32)
Baseline (Mean 6 SD) Final (Mean 6 SD) Intraocular Comparison Baseline (Mean 6 SD) Final (Mean 6 SD) Intraocular Comparison
EZW (mm) 2438 6 1646 1901 6 1423 P < .0001 2420 6 1758 1922 6 1482 P < .0001
Nasal ONL thickness (mm) 66.4 6 11.9 59.1 6 10.4 P < .0001 66.6 6 11.3 61.0 6 10.9 P ¼ .0036
Temporal ONL thickness (mm) 66.3 6 9.0 59.4 6 8.8 P ¼ .0006 64.4 6 11.1 58.0 6 8.6 P ¼ .0003
Nasal IRL thickness (mm) 105.8 6 46.5 104.0 6 49.5 P ¼ .9851 110.8 6 45.2 103.2 6 45.0 P ¼ .0042
Temporal IRL thickness (mm) 102.4 6 45.9 105.1 6 44.8 P ¼ .0958 102.7 6 43.6 99.1 6 42.9 P ¼ .1238
EZW ¼ ellipsoid zone width; IRL ¼ inner retinal layer; OCT ¼ optical coherence tomography; ONL ¼ outer nuclear layer; SD ¼ standard
deviation.
Two-tailed Wilcoxon signed rank test was used to investigate differences between baseline and final values with significance level alpha set
at 0.05.
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FIGURE 3. Scatterplot of interocular ellipsoid zone width
(EZW) at baseline for all study subjects with RPGR-associated
retinopathy, right eyes corresponding to left eyes. Spearman cor-
relation coefficient, rs [ 0.931, P < .0001 indicates a very
strong and significant interocular correlation.annual constriction rates of 176.6 mm/year (7.98%/year)
for right eyes and 173.1 mm/year (7.66%/year) for left
eyes in our study are comparable to that previously reported
for XLRP.20,22 Birch and associates found a decrease of
248 mm/year (7%/year) in their cohort of 28 XLRP
patients with a cohort baseline EZW of 3576 mm. Details
regarding causative genes for disease were not provided,
nor was justification on how they chose which eye of
their subjects for analysis.20
Our EZW annual constriction rate is less than that
described by Cai and associates of 289 mm/year (9.6%/
year) in their cohort of 26 XLRP patients, 25 of whom
had mutations in RPGR, with no information provided
on the exact sequence variants.22 Uniocular data wereVOL. 178 SPECTRAL-DOMAIN OCT INanalyzed in their study, with ocular selection made on
the basis of the eye with a clearer EZ band for analysis,
with a mean baseline EZW of 3410 mm. Thirty-three pa-
tients with ADRP were also studied for comparison and a
slower annual progression rate of 115.6 mm/year was found
(3.4%/year).22
The baseline EZW of 2438 mm and 2420 mm for right
and left eyes, respectively, indicates that our cohort as a
whole is composed of patients with relatively more
advanced disease, in comparison with the other 2 afore-
mentioned studies. The negative correlation of baseline
EZW with age in our cohort is consistent with increasing
disease severity with age as a consequence of retinal degen-
eration. The possibility of decreasing rates of progression
with advancing disease as the transition zone approaches
the fovea has previously been raised.20,38 This hypothesis
is supported by our finding of a strong and significant
correlation between rate of EZW constriction and
baseline EZW, and is reflected in a further analysis of
EZW constriction rates subsequent to the division of our
cohort into 2 age groups, each falling on either side of
the mean presentation age. Subjects under 19 years of age
have a greater rate of EZW constriction compared with
those 19 years or older (right eyes: 198.5 mm/year for
<19 years, 154.7 mm/year for >_19 years; left eyes:
228.3 mm/year for <19 years, 117.78 mm/year for >_19
years). Knowledge of disease duration may serve as a
better correlate of disease severity and progression rates.
It will likely, however, prove challenging to precisely
calculate disease duration, as one would need to establish
the exact time when symptoms of nyctalopia first
occurred/retinal dysfunction-degeneration commenced,
in the context of the early onset of disease in childhood
typical of RPGR-associated RP. In our study, we have
used numerical age as an approximation for disease
duration.
To the best of our knowledge, this is the first study to
characterize disease progression in both eyes of subjects23RPGR RETINOPATHY
TABLE 3. Ellipsoid Zone Width and Outer Nuclear Layer Progression Rates for Study Subjects With RPGR-Associated Retinopathy
Right Eyes (N ¼ 32) Left Eyes (N ¼ 32)
Interocular ComparisonMean (6 SD) 95% CI for Mean Mean (6 SD) 95% CI for Mean
Rate of EZW constriction (mm/yr) 176.6 6 130.1 129.7–223.5 173.1 6 146.8 120.1–226.0 P ¼ .8609
Rate of nasal ONL thinning (mm/yr) 2.71 6 3.83 1.33–4.10 2.57 6 5.21 0.70–4.45 P ¼ .1619
Rate of temporal ONL thinning (mm/yr) 2.44 6 4.01 0.99–3.88 2.48 6 4.70 0.78–4.17 P ¼ .8465
Average rate (nasal and temporal) of ONL
thinning (mm/yr)
2.58 6 2.85 1.55–3.60 2.52 6 3.54 1.25–3.80 P ¼ .6735
Intraocular comparison between nasal and
temporal ONL thinning rates
P ¼ .9922 P ¼ .4716
EZW ¼ ellipsoid zone width; ONL ¼ outer nuclear layer.
Positive values signify EZW constriction or ONL thinning. Two-tailed Wilcoxon signed rank test was used for statistical testing with
significance level alpha set at 0.05.
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FIGURE 4. Scatterplot of interocular ellipsoid zone width
(EZW) constriction rates for all study subjects with RPGR-
associated retinopathy, right eyes corresponding to left eyes.
Spearman correlation coefficient, rs [ 0.627, P [ .0002
indicates a strong and significant interocular correlation in
EZW progression.
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FIGURE 5. Scatterplot of ellipsoid zone width (EZW)
constriction rates vs EZW at baseline for study subjects with
RPGR-associated retinopathy. There is a strong and significant
correlation indicating greater progression rates in eyes with
larger EZW (rs[ 0.714, P< .0001).with molecularly proven RPGR-associated RP with a
follow-up duration of 3.1 years. The strong and significant
correlation in baseline interocular EZW and interocular
EZW rates of progression, together with a lack of significant
differences in rates of progression, imply symmetry between
eyes.
The direct measurement of EZW on transfoveal line
scans is believed to be the most ‘‘practical’’ and ‘‘effective’’
method of assessing progression over other methods of
quantifying thickness of various retinal layers across an
entire volume scan.21 This latter method involves the seg-
mentation of retinal layers, for example the outer nuclear
layer for all B-scans that form the volume scan to derive
a ‘‘global’’ average thickness value that encompasses the24 AMERICAN JOURNAL OFentire transition zone from healthy to diseased retina. It
has, however, been demonstrated that any measurable
change with this method is minimal at best.21 This is not
unexpected, as region C of the transition zone where EZ
disappearance occurs19 is where disease is most active, as
exemplified by the sharp drop in retinal sensitivity
compared to the central and peripheral regions, which
would be included in a global average thickness value,
likely resulting in the dilution and loss of the potential
identification of progression.
Herein we have described an alternative attempt to
quantify ONL thickness by taking serial ONL thickness
measures at specific points, which we term ‘‘transition
points,’’ that are located within region C of the transitionJUNE 2017OPHTHALMOLOGY
zone where photoreceptor degeneration is actively occur-
ring. The technique of foveal registration allows measure-
ments to be made at similar locations on sequential OCT
images. To the best of our knowledge, this method has not
been undertaken in previous studies. The ability to opti-
mally magnify images to enable clearer delineation of
retinal layers without pixellation was preserved, as images
were not exported out of the vendor software. Despite
this, we could not detect any significant correlation be-
tween ONL thinning rates and age, or between right
and left eyes. This may be owing to the inclusion of
OPL and Henle fibers (which is dominated by fibersVOL. 178 SPECTRAL-DOMAIN OCT INfrom the foveal cones at the parafovea) in our ONL mea-
surements. Likewise, we cannot rule out the effect this had
on the findings of borderline significance in the lower
ONL thinning rate for the null allele group, despite insig-
nificant differences in EZW constriction rates. This may,
however, warrant further investigation in future studies.
In conclusion, we have provided structural data on pro-
gression rates for RPGR-associated RP as obtained from
OCT-derived metrics. The finding that overall rate of pro-
gression in both eyes is similar has implications for future
gene therapy trials where 1 eye could potentially serve as
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